Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05489783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glioma Developmental and HyperActive Ras Tumor (DHART) Board

StatusRecruiting
PhaseNot specified
Started2022-07-29
View on ClinicalTrials.gov ↗
This study will collect medical records, scan results, and complete surveys to create a registry about people with a neurofibromatosis type 1-associated brain tumor (NF1-associated glioma). A registry is a collection of health information about individuals, and it is usually focused on a specific diagnosis or condition. This registry study will help the researchers learn more about the diagnosis, treatment, and quality of life of people with NF1-associated glioma. The researchers want to understand what happens as a result of different treatments for NF1-associated glioma and how these treatments and the disease itself affect people's lives over a period of time. Information collected during this study could affect how doctors diagnose, test, and treat NF1-associated glioma, and the study could help future patients with this type of cancer.

Amendment history 2 changes detected by DataLookout

2026-09-01
critical
Primary completion pushed: 2026-07-31 → 2027-07-31
2026-09-01
minor
Completion pushed: 2026-07-31 → 2027-07-31
Trial Details
NCT Number NCT05489783
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Glioma
Enrollment 50 participants
Start Date 2022-07-29
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-31